Management of the N0 neck in recurrent laryngeal squamous cell carcinoma

Abstract

Abstract. The most effective therapeutic approach for the node-negative (N0) neck in patients with recurrent laryngeal squamous cell carcinoma (SCC) remains a subject of dispute. In the present study, the records of 163 patients with recurrent laryngeal SCC were retrospectively reviewed. All patients had a N0 neck at recurrence. At the time of recurrence, the N0 neck was managed using a wait-and-see strategy (observation group) or treatment (treatment group). A total of 125 (76.7%) patients accepted the wait-and-see strategy and 38 (23.3%) patients underwent treatments, including surgery, radiotherapy and/or chemotherapy. The Kaplan-Meier method with the computation of log-rank was used for analysis of survival. The t-test, χ 2 test or Fisher's exact test was used for comparisons of non-survival data in the groups. P<0.05 was considered to indicate a statistically significant difference in the two-sided tests. The 3-and 5-year overall survival rates after recurrence were 64.5 and 54.6% for the observation group, and 49.9 and 42.5% for the treatment group, respectively (P=0.011). The present study suggests that a wait-and-see policy is a satisfactory management option for the N0 neck in recurrent laryngeal SCC.

Is routine neck dissection warranted at salvage laryngectomy?

“…In a large study by Li et al, the wait and watch group had better overall survival than the patients who received any kind of treatment to the neck, confirming the safety of the wait and watch approach. 31 We compared the outcomes between pathological node positive and pathological node negative patients. Presence of occult The Journal of Laryngology & Otology metastasis was not associated with inferior survival outcome in our study.…”

Upregulation of MiR-196a promotes cell proliferation by downregulating p27kip1 in laryngeal cancer

“…The prognosis for patients in the advanced stage is still very poor [ 2 ]. In China, the 30-year survival rates of patients with laryngeal cancer has improved moderately or even decreased in part due to the relatively high local recurrence [ 3 ]. Hence, there is a pressing need to identify both novel highly sensitive biomarkers and new targets for therapeutic intervention for laryngeal cancer which may aid the diagnosis and improve patient outcomes.…”